Ashley Henson
Family · Tupelo, MSNPI 1144669649
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 614 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,441, 3.1 times the $1,105 reported in 2021. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 614 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$2K
- Boehringer Ingelheim$1K
- Inspire Medical Systems, Inc.$818
- Harmony Biosciences LLC$769
- Mallinckrodt Hospital Products Inc.$451
- plus $5K from 30 others
What the payments were for
- Travel & lodging$4404%
- Food & beverage$11,34596%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 81 | $2,100 |
| GSK | 161 | $1,835 |
| Boehringer Ingelheim | 62 | $1,092 |
| Inspire Medical Systems, Inc. | 8 | $818 |
| Harmony Biosciences LLC | 30 | $769 |
| Mallinckrodt Hospital Products Inc. | 26 | $451 |
| Regeneron Healthcare Solutions, Inc. | 19 | $433 |
| Merck | 22 | $430 |
| Jazz Pharmaceuticals Inc. | 19 | $421 |
| Insmed, Inc. | 21 | $407 |
| Sanofi | 18 | $353 |
| Actelion Pharmaceuticals US, Inc. | 17 | $312 |
| Novartis | 15 | $256 |
| Genentech USA, Inc. | 13 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $220 |
| United Therapeutics Corporation | 13 | $214 |
| Electromed, Inc. | 10 | $205 |
| Mylan Specialty L.p. | 10 | $164 |
| Verona Pharma, Inc. | 9 | $154 |
| Bayer | 9 | $150 |
| ANI Pharmaceuticals, Inc. | 5 | $133 |
| Pulmonx Corporation | 6 | $131 |
| Amgen | 6 | $99 |
| Grifols USA, LLC | 3 | $87 |
| Viatris Specialty LLC | 4 | $82 |
| Body Vision Medical Inc. | 1 | $67 |
| Axsome Therapeutics, Inc. | 3 | $43 |
| Pfizer | 2 | $34 |
| Baxter Healthcare | 2 | $30 |
| Shionogi Inc | 1 | $24 |
| Fisher & Paykel Healthcare Inc | 1 | $21 |
| Ambu Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Breas Medical, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,834 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 44 | $498,789 |
| Dupixent PenDupilumab | 86 | $321,941 |
| OpsumitMacitentan | 21 | $265,629 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 331 | $230,421 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 157 | $82,894 |
| Fasenra PenBenralizumab | 11 | $61,558 |
| Breo ElliptaFluticasone/Vilanterol | 94 | $44,055 |
| Ambrisentan | 14 | $39,656 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $39,193 |
| Spiriva RespimatTiotropium Bromide | 35 | $23,585 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $13,620 |
| Spiriva HandihalerTiotropium Bromide | 17 | $11,940 |
| Incruse ElliptaUmeclidinium Bromide | 30 | $11,258 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 305 | $9,404 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $8,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,092 | $542,538106 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,835 | $372,510631 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $312 | $265,62921 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,100 | $47,62693 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Tupelo
- Jessica EatonTupelo$25K
- Lisa SandersTupelo$16K
- Amanda RobinsonTupelo$15K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.